Key Highlights

  • AVLN shares are trading down 5.39% to $25.68, against a prior close of $27.14.
  • The IPO lock-up expired on roughly 25.2 million common shares, plus options and warrants.
  • The stock sits near its one-year low of $22.24 and below its $31.37 50-day average.
  • The average analyst price target is about $60, including $57 from Morgan Stanley.
  • The lead program, inhaled pirfenidone candidate AP01, is in a Phase 2b trial.

Lock-Up Expiry Frees Roughly 25.2 Million Shares

Avalyn Pharma (NASDAQ:AVLN) shares are trading down 5.39% to $25.68 after the lock-up period following its April IPO expired. The lock-up covered roughly 25.2 million common shares, plus stock options and warrants, held by directors, executive officers and holders of substantially all outstanding stock. The expiry raises the prospect of added supply.

Shares opened at $27.00. The stock is near its one-year low of $22.24 and well below its 50-day average of $31.37, with a 52-week range of $22.24 to $40.17. The company went public at $18.00 per share, so shares remain about 43% above the offer price.

Inhaled Antifibrotic Pipeline Stays Unchanged

Avalyn Pharma, based in Boston, is a clinical-stage biopharmaceutical company that develops inhaled formulations of approved oral antifibrotic drugs. The aim is to deliver them directly to the lungs to improve efficacy and reduce the systemic side effects that cause patients to stop treatment. The pipeline targets pulmonary fibrosis and other interstitial lung diseases.

AP01, an inhaled pirfenidone, is in a Phase 2b trial for progressive pulmonary fibrosis. AP02, an inhaled nintedanib, is in a Phase 2 trial for idiopathic pulmonary fibrosis, and AP03, a fixed-dose combination of the two, is advancing toward Phase 1. Fundamentals are unchanged, with AP01 remaining the lead program.

Analyst Targets Near $60 Contrast With the Share Price

The consensus rating is Moderate Buy, with an average price target of about $60. Morgan Stanley's target is $57, and Raymond James rates the shares Outperform. The company has a market cap of $1.14 billion and a loss of $2.47 per share, with no approved products or revenue.

The drop looks stock-specific rather than sector-driven. The State Street Health Care Select Sector SPDR ETF is little changed, down 0.09%.

Share Supply, Not Science, Sets the Tone After the Lock-Up

The net takeaway is that the move reflects share supply rather than any change in the clinical story. Investors will watch how the stock trades relative to its one-year low and for progress on the AP01 Phase 2b trial.